NCT06911203View on ClinicalTrials.gov

A Study of BGM0504 in Participants With Obesity

PHASE2RecruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

January 11, 2026

Study Completion Date

January 11, 2026

Conditions

Obesity

Interventions

DRUG

BGM0504

Administered SC

DRUG

Tirzepatide

Administered SC

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

BrightGene Bio-Medical Technology Co., Ltd.

INDUSTRY